Meeting
2014 Gastrointestinal Cancers Symposium
Collective analysis of efficacy and safety of patients with advanced hepatocellular carcinoma (HCC) enrolled into early-phase clinical trials.
Authors
Vinu Madhusudanannair
The University of Texas Health Sciences Center at San Antonio, San Antonio, TX
Vinu Madhusudanannair , Brad H. Pollock , Norma Ketchum , Steven Weitman , John Sarantopoulos , Devalingam Mahalingam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 320)
DOI
10.1200/jco.2014.32.3_suppl.320
Abstract #
320
Poster Bd #
C35
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of low-dose apatinib in advanced hepatocellular carcinoma.
First Author: Lingbin Meng
Poster
2023 ASCO Annual Meeting
Efficacy and safety of first-line treatments for patients with advanced hepatocellular carcinoma: A systematic review and network meta-analysis.
First Author: Danni Li
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of TACE combined with anlotinib compared with TACE alone among patients with intermediate or advanced hepatocellular carcinoma (HCC): A randomized, controlled, phase II clinical study.
First Author: Hui Zeng
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Cabozantinib (CABO) tolerance and efficacy for patients with advanced hepatocellular carcinoma (HCC) after failure of sorafenib (SOR) in a French population: CLERANCE, a phase 4 trial.
First Author: Philippe Merle